Abstract:Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like-peptide-1 (GLP-1) are incretin hormones that stimulate insulin secretion and improve glycemic control in individuals with type 2 diabetes (T2D). Data from several cardiovascular outcome trials for GLP-1 receptor (GLP-1R) agonists have demonstrated significant reductions in the occurrence of major adverse cardiovascular events in individuals with T2D. Although the cardiovascular actions attributed to GLP-1R agonism have been extensively studied, little is known regarding the cardiovascular consequences attributed to GIP receptor (GIPR) agonism. As there is now an increasing focus on the development of incretin-based co-agonist therapies that activate both the GLP-1R and GIPR, it is imperative that we understand the mechanism(s) through which these incretins impact cardiovascular function. This is especially important considering that cardiovascular disease represents the leading cause of death in individuals with T2D. With increasing evidence that perturbations in cardiac energy metabolism are a major contributor to the pathology of diabetes-related cardiovascular disease, this may represent a key component through which GLP-1R and GIPR agonism influence cardiovascular outcomes. Not only do GIP and GLP-1 increase the secretion of insulin, they may also modify glucagon secretion, both of which have potent actions on cardiac substrate utilization. Herein we will discuss the potential direct and indirect actions through which GLP-1R and GIPR agonism impact cardiac energy metabolism while interrogating the evidence to support whether such actions may account for incretin-mediated cardioprotection in T2D.

The expanding incretin universe: from basic biology to clinical translation

[Primary pulmonary toxoplasmosis in an immunocompetent patient].

Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

Cellular mechanisms of incretin hormone secretion

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

Three-wavelength parallel optical fiber dispersion measurement using dual-heterodyne mixing.

Measurement of critical current and transient characteristics of a high-temperature superconductor tube with a pulsed current supply

[In vitro studies on the induction of an immunochemical attack using anti-AHP in the scope of cancer multiple-step therapy].

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut

New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin

The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

Control of insulin secretion by GLP-1

GLP-1, a powerful physiological incretin: an update.

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Progress in the Studies on Extra-Islet Effects of Incretin

Incretin-mediated control of cardiac energy metabolism

Antide and related antagonists of luteinizing hormone release with long action and oral activity.

Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials